Clinical Trial

Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

Study acronym: Neo IRENIE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial is for patients with stage 3 cutaneous melanoma and patients with mucosal melanoma who are able to have surgery to remove all tumour deposits. To improve the chance that melanoma will not recurr, new experimental combinations of a type of treatment called immunotherapy will be given before surgery.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-05-23; most recent amendment 2026-02-18.
Status change: Not Yet Recruiting → Recruiting 2026-02-18
Trial Details
NCT Number NCT06999980
Lead Sponsor Melanoma Institute Australia
Collaborators: Bristol-Myers Squibb
Conditions Cutaneous Melanoma, Mucosal Melanoma
Enrollment 494 participants
Start Date 2026-02-09
Primary Completion 2028-03 (estimated)
Study Completion 2038-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-19